News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 11, 2016, 07:00 ET Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


Jan 11, 2016, 06:00 ET Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments...


Jan 08, 2016, 07:00 ET Upcoming Corporate Presentations In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...


Sep 28, 2015, 06:00 ET Sorrento Therapeutics And City Of Hope Announce Exclusive License To Develop First-In-Class Immunotherapies Against Intracellular Targets

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that they have formed a new company – named LA Cell, Inc. (LA...


Sep 08, 2015, 13:30 ET Sorrento to Present at Upcoming Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical stage oncology company developing new treatments for cancer and...


Aug 10, 2015, 06:00 ET Sorrento's TNK Therapeutics Subsidiary Acquires Multiple Clinical Stage CAR-T Immunotherapy Programs

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired...


Aug 03, 2015, 06:00 ET Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an exclusive licensing agreement to develop and...


Jun 29, 2015, 13:06 ET Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has been added to the Russell 2000® Small Cap, Russell...


Jun 24, 2015, 09:00 ET ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Receipt of MUMS Drug Designation in Dogs

 ARK Animal Health, Inc., a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), , was granted a Minor Use/Minor...


May 26, 2015, 09:00 ET Sorrento to Present at the 2015 Jefferies Healthcare Conference and at Other Conferences

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical stage oncology company developing new treatments for cancer and associated...


May 18, 2015, 22:41 ET Sorrento crée TNK Therapeutics, une filiale spécialisée dans les immunothérapies cellulaires

- Le pipeline comprendra des CAR.TNKs™ en vente libre ainsi que des thérapies cellulaires et des immunothérapies...


May 18, 2015, 09:47 ET Sorrento gründet Tochtergesellschaft TNK Therapeutics mit Fokus auf zelluläre Immuntherapien

- Pipeline wird CAR.TNKs™'von der Stange' sowie komplementäre zelluläre und Immuntherapien umfassen  Sorrento...


May 18, 2015, 09:00 ET Sorrento Establishes TNK Therapeutics Subsidiary with Focus on Cellular Immunotherapies

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that it has formed a wholly-owned subsidiary, TNK (pronounced as "tank")...


May 18, 2015, 09:00 ET Sorrento richt dochterbedrijf TNK Therapeutics op dat zich zal focussen op cellulaire immunotherapieën

- Pijplijn bevat CAR.TNKs™ 'van de plank' evenals aanvullende cellulaire en immunotherapieën  Sorrento Therapeutics, Inc....


May 15, 2015, 16:26 ET NantWorks übernimmt Cynviloq™ für bis zu 1,3+ Milliarden USD

– Einstandszahlung in Höhe von 90+ Millionen USD und Meilensteinzahlungen von 1,2+ Milliarden USD – Sorrento behält Option...


May 15, 2015, 12:18 ET NantWorks acquiert Cynviloq™ pour un montant supérieur à 1,3 milliard de dollars US

-- Un versement initial de plus de 90 millions d'USD et des versements échelonnés de plus de 1,2 milliard d'USD --Sorrento garde la...


May 15, 2015, 10:38 ET NantWorks verwerft Cynviloq™ voor minimaal $ 1,3 miljard

--Betaling van minimaal $ 90 miljoen vooraf en minimaal $ 1,2 miljard aan mijlpaalbetalingen --Sorrento behoudt optie voor de gezamenlijke...


May 15, 2015, 09:00 ET NantWorks Acquires Cynviloq™ For Up To $1.3+ Billion

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the...


May 04, 2015, 10:44 ET Sorrento gibt positive Ergebnisse für TRIBECA™ Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) freut sich, positive Ergebnisse der vor kurzem analysierten pharmakokinetischen (PK) Daten aus seiner...


May 04, 2015, 09:46 ET Sorrento annonce des résultats positifs pour son étude d'homologation TRIBECA™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE) est heureuse d'annoncer des résultats positifs des données de pharmacocinétique...